Takamitsu Hosoya

Prof. Takamitsu Hosoya


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MMMichiko Muraki
Michiko Muraki
BOBisei Ohkawara
Bisei Ohkawara
THTakamitsu Hosoya
Takamitsu Hosoya
HOHiroshi Onogi
Hiroshi Onogi
JKJun Koizumi
Jun Koizumi
MHMasatoshi Hagiwara
Masatoshi Hagiwara
The regulation of splice site usage provides a versatile mechanism for controlling gene expression and for the generation of proteome diversity, playing an essential role in many biological processes. The importance of alternative splicing is further illustrated by the increasing number of human diseases that have been attributed to mis-splicing events. Appropriate spatial and temporal generation of splicing variants demands that alternative splicing be subjected to extensive regulation, similar to transcriptional control. The Clk (Cdc2-like kinase) family has been implicated in splicing control and consists of at least four members. Through extensive screening of a chemical library, we found that a benzothiazole compound, TG003, had a potent inhibitory effect on the activity of Clk1/Sty. TG003 inhibited SF2/ASF-dependent splicing of β-globin pre-mRNA in vitro by suppression of Clk-mediated phosphorylation. This drug also suppressed serine/arginine-rich protein phosphorylation, dissociation of nuclear speckles, and Clk1/Sty-dependent alternative splicing in mammalian cells. Consistently, administration of TG003 rescued the embryonic defects induced by excessive Clk activity in Xenopus. Thus, TG003, a novel inhibitor of Clk family will be a valuable tool to dissect the regulatory mechanisms involving serine/arginine-rich protein phosphorylation signaling pathways in vivo, and may be applicable for the therapeutic manipulation of abnormal splicing.

5 October 2010 in Nature Communications
Verified
Journal Article
Closed access
PDF file
YOYasushi Ogawa
Yasushi Ogawa
YNYosuke Nonaka
Yosuke Nonaka
TGToshiyasu Goto
Toshiyasu Goto
EOEriko Ohnishi
Eriko Ohnishi
THToshiyuki Hiramatsu
Toshiyuki Hiramatsu
MHMasatoshi Hagiwara
Masatoshi Hagiwara

5 September 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HSHironobu Sakaguchi
Hironobu Sakaguchi
YUYuta Uetake
Yuta Uetake
MOMasato Ohashi
Masato Ohashi
TNTakashi Niwa
Takashi Niwa
SOSensuke Ogoshi
Sensuke Ogoshi
THTakamitsu Hosoya
Takamitsu Hosoya

1 February 1994 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
THTakamitsu Hosoya
Takamitsu Hosoya
ETEiji Takashiro
Eiji Takashiro
TMTakashi Matsumoto
Takashi Matsumoto
KSKeisuke Suzuki
Keisuke Suzuki

25 July 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
TFTakeshi Fukuhara
Takeshi Fukuhara
THTakamitsu Hosoya
Takamitsu Hosoya
SSSaki Shimizu
Saki Shimizu
KSKengo Sumi
Kengo Sumi
TOTakako Oshiro
Takako Oshiro
MHMasatoshi Hagiwara
Masatoshi Hagiwara
Although the viral genome is often quite small, it encodes a broad series of proteins. The virus takes advantage of the host-RNA-processing machinery to provide the alternative splicing capability necessary for the expression of this proteomic diversity. Serine–arginine-rich (SR) proteins and the kinases that activate them are central to this alternative splicing machinery. In studies reported here, we use the HIV genome as a model. We show that HIV expression decreases overall SR protein/activity. However, we also show that HIV expression is significantly increased (20-fold) when one of the SR proteins, SRp75 is phosphorylated by SR protein kinase (SRPK)2. Thus, inhibitors of SRPK2 and perhaps of functionally related kinases, such as SRPK1, could be useful antiviral agents. Here, we develop this hypothesis and show that HIV expression down-regulates SR proteins in Flp-In293 cells, resulting in only low-level HIV expression in these cells. However, increasing SRPK2 function up-regulates HIV expression. In addition, we introduce SR protein phosphorylation inhibitor 340 (SRPIN340), which preferentially inhibits SRPK1 and SRPK2 and down-regulates SRp75. Although an isonicotinamide compound, SPRIN340 (or its derivatives) remain to be optimized for better specificity and lower cytotoxicity, we show here that SRPIN340 suppresses propagation of Sindbis virus in plaque assay and variably suppresses HIV production. Thus, we show that SRPK, a well known kinase in the cellular RNA-processing machinery, is used by at least some viruses for propagation and hence suggest that SRPIN340 or its derivatives may be useful for curbing viral diseases.

5 November 2015 in Chemistry Letters
Verified
Journal Article
Closed access
SYSuguru Yoshida
Suguru Yoshida
THTakamitsu Hosoya
Takamitsu Hosoya
Recent developments in aryne chemistry are reviewed with a particular focus on synthetic methods. This includes an overview of the precursors of arynes and their activators; the generation of arynes with functional groups and their ensuing reactivities; and the novel transformations achieved via aryne intermediates. These newly developed methods have enabled the synthesis of a variety of previously inaccessible aromatic compounds, allowing the construction of a diversity-enriched chemical library that will further facilitate future drug discoveries.